22 results about "Immune status" patented technology

The present invention relates to a composition for diagnosing immunodeficiency or a method for providing information for diagnosis thereof. By using the composition and the method according to one aspect, it is possible to simply and effectively diagnose immune-deficient conditions such as immunosuppression or immune paralysis.

The present invention relates to a biomarker HLA-DOA for sepsis-related diseases and a use thereof. The present invention provides a use of HLA-DOA or an active fragment or functional fragment thereof in the preparation of a product for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of sepsis-related diseases in a subject.

This invention discloses a prognostic and therapeutic suitability assessment model for hepatocellular carcinoma (HCC) based on mRNA vaccine antigens, and its construction method. First, the differences in gene expression between normal tissues and HCC tumors are analyzed to understand the mutations and genomic structural changes in HCC patients. Then, genes related to the level of antigen-presenting cell infiltration, as well as genes significantly related to overall survival and disease-free survival, are further selected from anomalously expressed and mutated genes to obtain candidate mRNA vaccine neoantigen targets. Based on the expression levels of these targets, patients are immunophenotyped to assess the patient population suitable for mRNA vaccines. Simultaneously, the relationship between target expression levels and patient prognosis is quantified to predict the probability of HCC patients achieving 3-year and 5-year overall survival. This invention can objectively and accurately assess treatment resistance and tumor immune status in HCC, improving the predictive accuracy of HCC treatment prognosis.

The invention discloses a 15-antibody combination for accurately detecting a mouse tissue immune cell subset and application of the 15-antibody combination. Aiming at the problems of large fluctuation and instability of detection results caused by adjustment of voltage and fluorescence compensation during detection by a flow cytometer and different processing modes during result analysis, the antibody combination disclosed by the invention takes monoclonal antibodies CD45, CD3, CD4, CD8, CD19, B220, Ly-6C, Ly-6G, MHC-II, CD11c, CD49b, CD62L, CD44 +, PD-1 and PD-L1 as effective components, and a stable and standard detection method for mouse tissue immune cell subsets is established. The method can analyze the proportion, number and distribution of various immune cells (T cells, B cells, NK cells, dendritic cells, mononuclear cells and granulocytes) in spleen, lung, liver, brain or kidney tissues of mice, can reflect the immune state of the mice and evaluate the immunosuppression state, and can be applied to the fields of disease models, drug evaluation, vaccine development and the like.

The present invention relates to a sepsis-related disease biomarker HLA-DQA and the use thereof. Provided in the present invention is the use of HLA-DQA or an active fragment and functional fragment thereof in the preparation of a product for early diagnosis, risk assessment, immune status assessment, prognosis prediction, and / or treatment regimen selection of a sepsis-related disease in a subject.

This invention relates to the field of traditional Chinese medicine composition technology, and particularly to an oral traditional Chinese medicine composition for treating multiple myeloma and its preparation method. It comprises the following components in parts by weight: Bupleurum chinense 10-12 parts, Cyperus rotundus 8-10 parts, Curcuma longa 8-10 parts, Oroxylum indicum 5-6 parts, Angelica sinensis 8-10 parts, Paeonia lactiflora 8-10 parts, Atractylodes macrocephala 10-12 parts, Poria cocos 10-12 parts, Codonopsis pilosula 8-10 parts, Glycyrrhiza uralensis (processed) 5-6 parts, Agrimonia pilosa 6-8 parts, Bambusa textilis 8-10 parts, Mentha haplocalyx 4-6 parts, and Zingiber officinale 4-6 parts. The composition provided by this invention not only directly inhibits the growth of myeloma cells, but also comprehensively improves the survival prognosis of model animals by regulating liver and spleen function, improving immune status, and reducing phlegm-heat and blood stasis. It provides a stable, safe, and easily promoted oral traditional Chinese medicine preparation for the clinical treatment of multiple myeloma.

The present invention relates to an immune sensitivity identification and regulation method based on the expression association of DUSP11 and nc886, and more specifically, to a method for providing immune response information, the method comprising a step for measuring the expression levels of DUSP11 and nc886. In the present invention, it was found that nc886 and DUSP11 are negatively correlated, and nc886 increases according to DUSP11 depletion in various cell types (epithelial cells, fibroblasts, and myofibroblasts). In addition, it was found that vtRNA in the 5'-PPP form increases upon depletion of DUSP11, thereby increasing immune response, but nc886 (vtRNA2-1) in the 5'-P form increases due to DUSP11 depletion, thereby decreasing immune response. That is, in the present invention, it was found that when the expression of nc886 in the 5'-P form increases as a result of DUSP11 depletion, inflammatory responses caused by IFN are alleviated due to the increased 5'-P-nc886, and thus the present invention can be used as a method for providing information on immune status using the correlation between nc886 and DUSP11.

Tumors use a variety of mechanisms to avoid the host's anti-tumor immune response. Humoral immune suppression is one of the mechanisms. Tumors produce circulating factors that can suppress antibody or complement-mediated immune responses to enhance their own survival. Mesothelin is a cell surface protein that is overexpressed by several cancer types that are associated with a microenvironment that exhibits immune suppression. Anti-mesothelin antibodies often suffer from such immune suppression microenvironments. However, an alternatively formatted anti-mesothelin antibody is effective in killing mesothelin-expressing cancers, independent of the tumor microenvironment immune status.

This invention discloses a set of biomarkers, scoring models, and applications for assessing immunotherapy response and / or prognosis in head and neck squamous cell carcinoma, relating to the field of biomedical technology. The biomarkers include ITGB1, FTH1, SPP1, CD3D, CXCL9, and IL2RB. The STRIDE score is obtained by calculating the geometric mean ratio of the expression levels of the aforementioned six biomarkers, which can be used to assess the likelihood of high or low response to immunotherapy and / or prognostic risk in subjects. This invention constructs a spatial domain scoring model based on the D4 and D5 / D6 spatial domains to obtain the STRIDE score, reflecting the patient's spatial immune status, thereby enabling the assessment of prognostic risk and the suitability of immunotherapy for patients with head and neck squamous cell carcinoma.

The present invention relates to a biomarker PAX5 for sepsis-related diseases and a use thereof. The present invention provides a use of PAX5 or an active fragment or functional fragment thereof in the preparation of a product for early diagnosis, risk assessment, immune status evaluation, prognostic prediction and / or treatment plan selection of a sepsis-related disease in a subject.

The invention provides a flow type detection method for expression and activation of peripheral blood Vgamma9 T cells of machin, and belongs to the technical field of biological detection. The detection method provided by the invention can synchronously and specifically identify the T cells expressing the Vgamma9 in the peripheral blood of cynomolgus monkeys and the activated subsets of the T cells, and realizes accurate distinguishing and quantitative analysis of target cell populations. The method is clear in operation process and stable and reliable in result, and an effective tool is provided for evaluating the immune state of cynomolgus monkeys. Establishment of the method is helpful for efficiently monitoring the influence of drugs on specific T cell subgroups in preclinical drug safety evaluation and immune pharmacological research, and provides key technical support for research, development and evaluation of related biological agents.

The invention discloses an immune state assessment method and system, and the method comprises the steps: collecting a peripheral blood sample through multicolor flow cytometry to obtain test data, carrying out the compensation processing of the test data, and storing the data in an FCS file format; performing normalization processing on the test data to adjust a value domain between 0 and 1; a plurality of unsupervised machine learning clustering algorithms are adopted to respectively perform clustering analysis on the test data, a plurality of clustering analysis results are evaluated through a contour coefficient, a Clinski-Harabasz index and a Davies-Bouldin index, and a target clustering algorithm and an optimal clustering number are determined; an immune state evaluation model is constructed based on a plurality of machine learning algorithms, model training is carried out to obtain a target evaluation model, final immune state scoring is carried out based on the target evaluation model, and the plurality of machine learning algorithms at least comprise a Light GBM algorithm, a random forest algorithm and an XGBoost algorithm. According to the method, the deep immune information is mined and the evaluation model is constructed, so that the immune state of the individual is accurately evaluated.

This invention discloses a biomarker for evaluating the immune status of COVID-19 vaccines and its application. The biomarker includes any one or a combination of at least two of the following SARS-CoV-2 viral peptides: M1, N16, N24, S15, S39, S44, S64, S82, S95, S104, or S115. This invention accurately identifies differences in peptide-specific antibody responses between asymptomatic and symptomatic patients. Through clustering heatmaps, it determines the differences in responses to peptides such as M1, N24, S15, S64, S82, S104, and S115 between vaccinated individuals and infected individuals. This effectively distinguishes between infected patients and vaccinated individuals, as well as between asymptomatic and symptomatic patients, providing a reference for COVID-19 treatment and peptide vaccine development.

The invention discloses an immune state and immune age assessment method and system based on a TCR immune repertoire, and belongs to the technical field of immune monitoring. A TCR sequencing result of a target person is obtained, the TCR sequencing result comprises first sequencing data corresponding to the target person, a multi-dimensional feature data set is determined according to the TCR sequencing result, and the immune state and the immune age of the target person are determined according to the multi-dimensional feature data set and a pre-training deep learning model, the pre-trained deep learning model is a multi-task model, and the beneficial effect of improving the accuracy of the immune state is achieved.

This invention discloses a method and system for predicting the immune status of cell lines based on tissue immune information. The method includes the following steps: S1, constructing a gene intersection expression matrix; S2, constructing a feature matrix; S3, identifying candidate shared functional gene modules across systems and establishing the correspondence between the candidate shared functional gene modules in tissue samples and cell line samples; S4, screening out significant shared functional gene modules; S5, dividing each significant shared functional gene module on the tissue sample side into positive immune-related modules and negative immune-related modules; S6, obtaining a set of key genes for positive immunity and a set of key genes for negative immunity; S7, constructing positive immune templates and negative immune templates respectively; S8, calculating the expression characteristics of the cell line sample to be tested on the set of key genes for positive immunity and the set of key genes for negative immunity, and comparing the similarity with the positive immune template and the negative immune template respectively. This invention achieves robust prediction of the immune status of cell lines.

This invention discloses a multiple sclerosis intervention suggestion generation system based on individual immune characteristics, comprising: a multi-source immune data acquisition and temporal standardization processing layer, a multi-scale immune feature extraction and immune status index calculation layer, and a non-therapeutic intervention scheme multi-objective optimization and generation layer. This invention has the following advantages and effects: the multi-source immune data acquisition and temporal standardization processing layer achieves temporal alignment, dimensional normalization, and missing value imputation of the original dataset of multi-dimensional immune features; the multi-scale immune feature extraction and immune status index calculation layer extracts features from the time domain, frequency domain, and nonlinear dynamics in parallel and fuses them to calculate the immune status index; and the non-therapeutic intervention scheme multi-objective optimization and generation layer generates non-therapeutic intervention schemes, thereby effectively solving the problems of difficulty in integrating multi-source heterogeneous immune data, incomplete immune status assessment, and lack of personalization and practicality in intervention suggestions.

The invention relates to a technical scheme in the field of immune regulation and control in high-toxicity klebsiella pneumoniae infection, and particularly discloses regulation and control of an IER3-CSF2 axis in high-toxicity klebsiella pneumoniae sepsis immune low reaction and application of the IER3-CSF2 axis in high-toxicity klebsiella pneumoniae sepsis immune low reaction. Researches find that after the Ier3 gene is knocked down, tissue damage in high-toxicity klebsiella pneumoniae infected sepsis is aggravated, and the survival rate is reduced. With the decline of CSF2 expression and the migration of macrophages to M2 type, the secretion of proinflammatory factors is insufficient, and the immune response is impaired. Further in-vitro cell experiments show that supplement of CSF2 can reverse reduction of expression of inflammatory factors. Based on the discovery, the invention provides an immune state evaluation method taking an IER3-CSF2 signal axis as a target spot and a potential immune regulation strategy, and the immune state evaluation method and the potential immune regulation strategy are suitable for development of an intervention scheme of bacterial infection, especially sepsis, and have important clinical transformation application value.

The invention relates to a solution for mitigating against transmitting, receiving or hosting transfers of infectious diseases through access to a user's health record via a mobile, cloud server-based application. The user's heath record data is stored in the application database, and can include immunization records, test results, and pre-existing conditions. This data is accessed using the mobile application interface by scanning a uniquely generated Quick Response (QR) code, and displayed through an application downloaded to a separate device, such as one owned by a venue. The user's code is scanned to display an immunity score and verified by the user's identification data, matched to data on the second device. This data can also be accessed by other users, such as venue owners who want to insure the health and safety of their patrons.

The present invention relates to methods for monitoring the immune status of a population by detecting and / or quantifying antibodies present in wastewater. The invention further provides methods and kits for monitoring the presence of an antibody to SARS-CoV-2 or a variant thereof within a population by detecting and / or quantifying SARS-CoV-2-specific antibodies in wastewater.

The invention discloses a traditional Chinese medicine vaginal suppository for treating female pelvic inflammation and a preparation method and application thereof, and relates to the field of traditional Chinese medicine preparations, the preparation method comprises the following steps: S1, mixing polygonum aviculare, radix rehmanniae, pepper and croton, crushing and sieving to obtain traditional Chinese medicine powder; s2, dividing the traditional Chinese medicine powder into two parts, and blending to form quick-release layer medicine slurry and slow-release layer medicine slurry; s3, injecting the slow-release layer medicine slurry into a mold cavity, cooling and curing, injecting the quick-release layer medicine slurry into the outer layer of the mold cavity, and performing pressure treatment and cooling to obtain a molded suppository; and S4, wrapping the formed suppository with a disinfection material, and mooring a thread which can be taken out to obtain the traditional Chinese medicine vaginal suppository. The suppository compatibility system not only eliminates pathogens, but also improves local microcirculation and immune states, so that the suppository is helpful for breaking the persistent circulation of chronic pelvic inflammation, thereby achieving the purposes of treating both symptoms and root causes and reducing disease relapse.

The invention relates to the technical field of biological detection reagents, in particular to a porcine interferon-gamma (IFN-gamma) double-antibody sandwich enzyme-linked immunosorbent assay kit and a detection method thereof. The invention provides a porcine interferon-gamma (IFN-gamma) double-antibody sandwich enzyme-linked immunosorbent assay kit. The porcine interferon-gamma (IFN-gamma) double-antibody sandwich enzyme-linked immunosorbent assay kit comprises an elisa plate coated with an IFN-gamma monoclonal antibody P2F6, a biotin-labeled monoclonal antibody P2C11, horse radish peroxidase labeled streptavidin, an IFN-gamma protein standard substance, a confining liquid, a sample or standard substance diluent, a developing liquid, a stopping liquid and a washing liquid. The porcine interferon-gamma (IFN-gamma) double-antibody sandwich enzyme-linked immunosorbent assay kit provided by the invention can efficiently, specifically and accurately detect IFN-gamma in porcine serum, and provides important technical support for evaluating the cellular immune state after a pig herd is vaccinated.

This invention relates to the field of biomedical technology, specifically disclosing a recombinant rabbit monoclonal antibody against human CD3, its preparation method, and its applications. This antibody, obtained by immunizing rabbits to elicit an anti-CD3 immune response, is derived through single-cell B-cell sorting, gene cloning, and a mammalian cell expression system, exhibiting high affinity and good specificity. The antibody can effectively recognize CD3-positive T cells in human peripheral blood and can be applied in flow cytometry, immunohistochemistry, and T cell function studies. Experimental results show that this antibody has advantages such as high titer, strong fluorescence signal, and low background, outperforming traditional murine anti-CD3 antibodies. Further, the amino acid sequences of the variable regions of the light and heavy chains of this antibody were obtained, enabling controllable and reproducible antibody expression. This antibody has significant scientific research value and promising industrial applications, suitable for various scenarios such as T cell marker detection, immune status assessment, and adjuvant research in immunotherapy.